Cargando…
Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
OBJECTIVES: Previous studies demonstrated equivalence in terms of efficacy and safety of biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching situations. Less is known about what happens when initiating a bsDMARD in a molecule naïve patient. The objectives of our study...
Autores principales: | Larid, Guillaume, Baudens, Guy, Dandurand, Alexis, Coquerelle, Pascal, Goeb, Vincent, Guyot, Marie Hélène, Marguerie, Laurent, Maury, Frédéric, Veillard, Eric, Houvenagel, Eric, Salmon, Jean-Hugues, Flipo, René-Marc, Gervais, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582272/ https://www.ncbi.nlm.nih.gov/pubmed/36275803 http://dx.doi.org/10.3389/fmed.2022.989514 |
Ejemplares similares
-
Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
por: Salmon, Jean-Hugues, et al.
Publicado: (2020) -
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019) -
Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014) -
GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017) -
Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)